Providing Constant Analgesia with OROS Ò Hydromorphone
|
|
- Leslie Adams
- 6 years ago
- Views:
Transcription
1 Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S19 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting Opioid Analgesic Providing Constant Analgesia with OROS Ò Hydromorphone Suneel Gupta, PhD, and Gayatri Sathyan, PhD ALZA Corporation, Mountain View, California, USA Abstract OROS Ò (ALZA Corporation, Mountain View, CA, USA) hydromorphone is a unique, once-daily formulation of the potent opioid hydromorphone that is being evaluated for the treatment of moderate-to-severe chronic pain. It uses a patented Push-Pull Ô (ALZA Corporation) osmotic pump system to deliver hydromorphone in a continuous, monophasic manner over 24 hours, resulting in minimal peak-trough plasma-level fluctuation. Peak concentrations are achieved approximately 16 hours after administration, with levels equivalent to approximately 80% of peak attained within just 6 hours. The apparent halflife of OROS Ò hydromorphone is 7e15 hours and steady-state concentrations are achieved after 2 days of dosing. The pharmacokinetics of OROS Ò hydromorphone are dose proportional and are not affected significantly by environmental factors (ph or agitation) or the presence of food. These pharmacokinetic characteristics suggest that OROS Ò hydromorphone is well suited to provide consistent, prolonged analgesia in patients with chronic pain. J Pain Symptom Manage 2007;33:S19eS24. Ó 2007 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. Key Words Hydromorphone, sustained-release, pharmacokinetics, chronic pain Introduction Chronic pain is a common condition that affects up to 55% of the population worldwide. 1 It is typically challenging to manage, particularly in the ambulatory setting, in which clinicians rely on orally administered agents to provide long-lasting pain relief. The Address reprint requests to: Suneel Gupta, PhD, ALZA Corporation, 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039, USA. SGupta7@alzus.jnj.com Accepted for publication: September 1, Ó 2007 U.S. Cancer Pain Relief Committee Published by Elsevier Inc. All rights reserved. fluctuating plasma drug levels produced by short-acting, immediate-release (IR) formulations of analgesics have been associated with adverse effects and breakthrough pain. In contrast, extended-release formulations achieve more stable plasma drug concentrations that potentially provide around-the-clock pain control and less breakthrough pain (Fig. 1). OROS Ò hydromorphone is a unique, oncedaily formulation that uses the patented OROS Ò Push-PullÔ technology (ALZA Corporation, Mountain View, CA, USA) to deliver the potent opioid hydromorphone. The OROS Ò technology provides continuous, monophasic drug release over 24 hours, 2 which achieves consistent, long-lasting analgesia. 3,4 The /07/$esee front matter doi: /j.jpainsymman
2 S20 Gupta and Sathyan Vol. 33 No. 2S February 2007 Drug A Immediate Release (q4h) Drug B Biphasic Controlled Release (q12h) Drug C Monophasic Extended Release (q24h) Pain Time Increased Pain Intensity Overall treatment desire for around-the-clock management with limited breakthrough pain Fig. 1. Fluctuating plasma concentrations associated with IR and biphasic controlled-release formulations of pain medications can result in breakthrough pain. purpose of this brief review is to describe the OROS Ò hydromorphone dosage form and summarize its pharmacokinetic/pharmacodynamic attributes, which are well suited for the control of chronic pain. Hydromorphone Pharmacokinetics Hydromorphone is a hydrogenated ketone of morphine that has been used to treat pain for nearly 80 years. 5 Its pharmacokinetic profile has been well defined and demonstrated to be independent of dose (i.e., first-order kinetics). 6 The absorption of IR hydromorphone occurs primarily in the upper small intestine and is biphasic (i.e., an initial rapid phase of up to two hours followed by a slow phase). 7 Hydromorphone is rapidly absorbed into the systemic circulation. Analgesia is measurable within 30 minutes of oral administration and it endures for approximately four hours. 7 Maximum plasma hydromorphone concentrations are achieved within one hour of dosing. 8 Hydromorphone is moderately lipid soluble, highly water soluble, and rapidly distributed into skeletal muscle, kidneys, liver, intestine, lungs, spleen, and brain. Extensively metabolized by the liver, 7 hydromorphone has a mean effective elimination half-life of 2.6 hours and a high volume of distribution (1.22 L/kg). 9 OROS Ò Technology OROS Ò osmotic technology has been used clinically for more than two decades to optimize the release of orally administered medications. Dosage forms that use OROS Ò technology vary greatly, as the design of each system is unique and formulated to provide a specific delivery pattern. 10 OROS Ò hydromorphone uses a patented Push-PullÔ osmotic pump (Fig. 2) to provide 24-hour monophasic delivery of hydromorphone. 11 The tablet core is made up of two layers: a drug layer containing hydromorphone and excipients and a push layer containing osmotic agents. These layers are surrounded by a semirigid, nondissoluble membrane that has a precision laser-drilled hole for drug delivery. Water from the gastrointestinal tract enters the pump at a controlled rate through the semipermeable membrane. This causes the hydromorphone in the drug layer to go into suspension and the osmotic layer to swell. As it expands, the osmotic layer pushes against the drug layer, and hydrated hydromorphone flows into the gastrointestinal tract through the delivery orifice at the same rate as water enters the core. The membrane itself does not dissolve and the tablet passes through the gastrointestinal tract intact. Consistency of OROS Ò Hydromorphone Release Utilization of the OROS Ò Push-PullÔ osmotic pump ensures a constant, monophasic delivery of hydromorphone over a 24-hour period. Measurable release of hydromorphone begins approximately two hours after administration (the beginning of water permeation). Thereafter, the rate of release is constant up to 18 h (Fig. 3). 2 The rate of release of hydromorphone from the OROS Ò system is
3 Vol. 33 No. 2S February 2007 Constant Analgesia With OROS Ò Hydromorphone S21 Laser-Drilled Hole (point of drug release) Rate-Controlling Membrane Hydromorphone HCl Hard Shell (clear or colored overcoat) Osmotic Pump (Push layer) Fig. 2. Cross-section of the OROS Ò patented Push-PullÔ pump. consistent across a range of doses (Fig. 3), 2 which results in similar rates of absorption into the systemic circulation for all doses (Fig. 4). 1,12 The osmotic driving force of OROS Ò and protection of the drug until the time of release eliminate the variability of drug absorption and metabolism often caused by food, gastric ph, and motility. 13e17 Hence, as with other OROS Ò formulations, drug release from OROS Ò hydromorphone is independent of ph and agitation. 10 Pharmacokinetic Characteristics The pharmacokinetics of OROS Ò hydromorphone are significantly different from those of IR hydromorphone and are consistent with those desired for the long-term management of chronic pain. IR hydromorphone is rapidly released, resulting in a peak plasma concentration that occurs within one hour of administration. In contrast, OROS Ò hydromorphone is released more slowly, resulting in a later, lower peak (Fig. 5). 3 In healthy volunteers, peak plasma hydromorphone concentrations after single-dose OROS Ò hydromorphone administration occurred approximately 13 to 16 hours after administration. 4 Plasma concentrations reached a broad, relatively flat plateau region within 6 to 8 hours postdose and remained in this plateau region until approximately 24 hours postdose. The half-life Cumulative Percent Released (LC) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% OROS hydromorphone 8 mg OROS hydromorphone 16 mg OROS hydromorphone 32 mg OROS hydromorphone 64 mg Fig. 3. Release rate of hydromorphone from OROS Ò hydromorphone is consistent across dose strengths.
4 S22 Gupta and Sathyan Vol. 33 No. 2S February Plasma Hydromorphone Concentration (ng/ml) OROS hydromorphone 1x8 mg OROS hydromorphone 1x16 mg OROS hydromorphone 1x32 mg OROS hydromorphone 1x64 mg Hours From Dosing Fig. 4. Mean plasma hydromorphone concentration vs. time on log scale. of OROS Ò hydromorphone ranged from approximately 7 to 8 hours for all dose strengths (8, 16, and 32 mg). An open-label, randomized, crossover, multiple-dose study compared IR hydromorphone 4 mg every 6 hours with once-daily OROS Ò hydromorphone 16 mg in 18 healthy subjects. 4 Once-daily OROS Ò hydromorphone achieved a much flatter plasma-concentration profile than IR hydromorphone (Fig. 6). After 48 hours, steady-state concentrations were achieved, and OROS Ò hydromorphone plasma concentrations were maintained above the minimum IR hydromorphone plasma concentrations for each 24-hour dosing interval. The pharmacokinetic profile of OROS Ò hydromorphone is dose proportional. In an open-label, four-way crossover study conducted in 31 healthy volunteers, maximum plasma hydromorphone concentrations were achieved approximately 16 to 17 hours after administration of OROS Ò hydromorphone 8, 16, 32, and 64 mg. 12 All doses had similar elimination half-lives (mean, 10.6e11 hours) and produced plasma concentrations that were maintained at or near maximum levels for approximately 30 hours. The pharmacokinetics of OROS Ò hydromorphone are minimally affected by food. In an open-label, three-way, crossover study conducted in 30 healthy volunteers, the mean maximum plasma concentration was increased slightly by administration with a high-fat meal (1.352 vs ng/ml); however, this difference was not considered to be clinically significant. 14 Similarly, the extent of absorption was Hydromorphone (ng/ml) mg IR hydromorphone 8 mg OROS hydromorphone 16 mg OROS hydromorphone 32 mg OROS hydromorphone (n=12) Fig. 5. Plasma concentration vs. time profiles of IR hydromorphone and OROS Ò hydromorphone after singledose administration. 4
5 Vol. 33 No. 2S February 2007 Constant Analgesia With OROS Ò Hydromorphone S Hydromorphone (ng/ml) mg OROS hydromorphone t mg IR hydromorphone q6h Fig. 6. Steady-state plasma concentration vs. time profiles of IR hydromorphone and OROS Ò hydromorphone. 4 similar in fasted and fed groups (mean AUC 0e48, ng$h/ml in the fasting state and ng$h/ml in the fed state and mean AUC 0eN, ng$h/ml in the fasting state and ng$h/ml in the fed state). The 90% confidence intervals for the ratios of the product means for AUC 0e48 and AUC 0eN were within 80% to 125% (84.9%, 103.7%, and 81%, 99.4%, respectively) indicating that the differences were minimal and not clinically significant. Under fed vs. fasting conditions, the median time to maximum plasma concentration was 4 hours earlier (12 vs. 16 hours, respectively; P ¼ ; 90% confidence interval for difference between product medians: , ), and the mean half-life was approximately 2 hours shorter (12.5 vs hours). The plasma-concentration time profiles of OROS Ò hydromorphone under fasted and fed conditions are shown in Fig. 7. The pharmacokinetic profile of OROS Ò hydromorphone in patients with chronic pain appears to be similar to that in healthy individuals. Table 1 presents data from five patients with chronic pain requiring daily opioid therapy who received OROS Ò hydromorphone 16 mg daily for 5e10 days in an open-label, repeated-dose study, and from 18 healthy subjects who received OROS Ò hydromorphone 16 mg daily for four days in an open-label, two-way crossover, multiple-dose study. 4 Overall, the exposure to OROS Ò Hydromorphone (ng/ml) mg OROS hydromorphone Fasted 16 mg OROS hydromorphone Fed Fig. 7. The pharmacokinetics of OROS Ò hydromorphone are minimally affected by food. 13
6 S24 Gupta and Sathyan Vol. 33 No. 2S February 2007 Table 1 Steady-State Pharmacokinetic Profile of OROS Ò Hydromorphone (16 mg qd) in Healthy Volunteers and Patients with Chronic Pain 4 Parameter hydromorphone was similar in both groups (mean [SD] AUC 0e24, 46.1 [10.6] ng$h/ml in patients with chronic pain and 45.6 [16.8] ng$h/ml in healthy subjects). Summary The pharmacokinetic characteristics of OROS Ò hydromorphone are well suited to provide consistent, prolonged analgesia in patients with chronic pain. This once-daily formulation provides constant drug delivery over a 24-hour period with minimal peaktrough fluctuation. Peak plasma concentrations are achieved approximately 16 hours after administration, with levels equivalent to approximately 80% of peak attained within 6 hours. The apparent elimination half-life of OROS Ò hydromorphone is 7e15 hours, and steady-state plasma concentrations are achieved after two days of dosing. The pharmacokinetics of OROS Ò hydromorphone are dose proportional, and are not significantly affected by environmental factors (ph or agitation) or the presence of food. References Healthy Volunteers, Mean (SD) Patients with Chronic Pain, a Mean (SD) (n ¼ 18) (n ¼ 5) C max, ng/ml 2.62 (0.83) 2.93 (0.6) T max, hours 14.7 (5.1) 9.8 (5.8) C min, ng/ml 1.16 (0.47) 1.25 (0.31) AUC 0e24,ng$h/mL 45.6 (16.8) 46.1 (10.6) Fluctuation, % 83 (31) 89 (16) a Patients with chronic pain defined as those who required 32e300 mg/day morphine. 1. International Association for the Study of Pain. How prevalent is chronic pain? Pain Clin Updates 2003;XI(2):1e4. 2. Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002;97:827e Angst MS, Drover DR, Lötsch J, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001; 94:63e Data on file. ALZA Corporation, Mountain View, CA. 5. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29(5 Suppl):S57eS Hill HF, Coda BA, Tanaka A, Schaffer R. Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. Anesth Analg 1991;72:330e Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001;9: 84e Durnin C, Hind ID, Ghani SP, Yates DB, Cross M. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR). Proc West Pharmacol Soc 2001;44: 73e Vallner JJ, Stewart JT, Kotzan JA, et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981;21: 152e Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS Ò ). A retrospective study. Drug Saf 2002;25:1021e Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel once-daily, OROS Ò osmotic technology, extendedrelease hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23:355e Gupta S, Xu E, Sathyan G. Pharmacokinetic investigation of dose proportionality across the OROS Ò hydromorphone dose range. Proceedings of the 11th World Congress on Pain. Sydney, Australia, August 21-26, IASP Press: 691; Abstract 179eP OROS Ò Oral Delivery Technology. Available from Accessed September 16, Sathyan G, Xu E, Gupta S. Effect of food on the pharmacokinetic profile of OROS Ò hydromorphone. Presented at the 11th World Congress on Pain. Sydney, Australia, August 21-26, IASP Press: 632e633; Abstract 1796eP Sathyan G, Hu W, Gupta SK. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J Clin Pharmacol 2001;41:187e Dmochowski R, Chen A, Sathyan G, et al. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J Clin Pharmacol 2005;45:961e Eckenhoff B, Theeuwes F, Urquhart J. Osmotically activated dosage forms for rate-controlled drug delivery. Pharm Technol 1981;5:35e44.
Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
Devarakonda et al. SpringerPlus 2013, 2:625 a SpringerOpen Journal RESEARCH Open Access Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationDecentralised Procedure. Public Assessment Report
Decentralised Procedure Public Assessment Report Hydromorphon Develco 1 x täglich Hydromorphon Aristo long Hydromorphon-neuraxpharm 1 x täglich 4 / 8 / 16 / 32 mg Retardtabletten Hydromorphone hydrochloride
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationSZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science
SZENT ISTVÁN UNIVERSITY Doctoral School of Veterinary Science Comparative pharmacokinetics of the amoxicillinclavulanic acid combination in broiler chickens and turkeys, susceptibility and stability tests
More informationPBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak
PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak Dwaipayan Mukherjee, Ph.D. Jiuhong Zha, Ph.D. Rajeev Menon, Ph.D. Mohamad Shebley, Ph.D. Clinical
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationA Pet Owner s Guide to Joint Health for Dogs
A Pet Owner s Guide to Joint Health for Dogs What is Cosequin? Cosequin is a patented, scientifically researched nutritional supplement dispensed by thousands of veterinarians since 1992 to help dogs maintain
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationJoint Health Supplement
Joint Health Supplement A Pet Owner s Guide to Joint Health for Dogs What is Cosequin? Cosequin is a patented, scientifically researched nutritional supplement dispensed by thousands of veterinarians for
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationEuropean public MRL assessment report (EPMAR)
15 January 2013 EMA/CVMP/914694/2011 Committee for Medicinal Products for Veterinary Use (CVMP) European public MRL assessment report (EPMAR) Fenbendazole (extension to chicken and extrapolation to all
More informationPublic Assessment Report Scientific discussion. Amlodipin Accord (amlodipine besilate)
Public Assessment Report Scientific discussion Amlodipin Accord (amlodipine besilate) SE/H/842/01-02/MR This module reflects the scientific discussion for the approval of Amlodipin Accord 5 mg and 10 mg
More informationPOPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS Emmanuel Chigutsa 1, Sandra Meredith 1, Lubbe Wiesner 1, Nesri Padayatchi 2, Joe
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
1 SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Exflow 10 mg/g powder for use in drinking water for cattle (calves), pigs, chickens, turkeys and ducks Exflow Vet 10
More informationMoxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationWhat dose of methadone should I use?
What dose of methadone should I use? Professor Derek Flaherty BVMS, DVA, DipECVAA, MRCA, MRCVS RCVS and European Specialist in Veterinary Anaesthesia SPC dose rates for Comfortan dogs: 0.5-1.0 mg/kg SC,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationsingle intravenous and oral doses and after 14 repeated oral
Br. J. clin. Pharmac. (1986), 22, 21-25 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily J. K. FAULKNER
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationdiscover the nextgeneration of flea & tick protection NEW TASTY CHEW ONE CHEW ONCE A MONTH
discover the nextgeneration of flea & tick protection KILLS FLEAS KILLS TICKS ONE CHEW ONCE A MONTH TASTY CHEW NEW Now there s a new oral treatment that offers effective flea AND tick control on dogs for
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Orafluke 10% w/v Oral Suspension. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substances per ml Fenbendazole 100 mg Rafoxanide
More informationCommonly Used Analgesics
Commonly Used Analgesics The following analgesics are intended for general use in the species of laboratory animals commonly used at NEOUCOM. The animals genetic background and other factors may have a
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystatin Orifarm, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients with known effect: - Methyl parahydroxybenzoate
More informationINTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre
INTRODUCTION TO WILDLIFE PHARMACOLOGY Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre General Pharmacology Factors That Affect Drug Absorption The dosage form Blood supply to the area
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More information4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals
1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationPharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationThe world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF
The world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF NOTHING IS SIMPLER THAN POUR-ON RELIEF FOR PAIN, FEVER AND ACUTE INFLAMMATION easy to dose easy to apply easy on animals
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ZANTEL 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Per tablet Praziquantel 50.0 mg Fenbendazole 500.0 mg
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationDose-related thermal antinociceptive effects of intravenous hydromorphone in cats
Veterinary Anaesthesia and Analgesia, 2007, 34, 132 138 doi:10.1111/j.1467-2995.2006.00311.x RESEARCH PAPER Dose-related thermal antinociceptive effects of intravenous hydromorphone in cats Kirsten Wegner
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NexGard 11 mg chewable tablets for dogs 2-4 kg NexGard 28 mg chewable tablets for dogs > 4-10 kg NexGard 68 mg chewable
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Orafluke 5% w/v Oral Suspension. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1ml of suspension contains: Active Substances
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion SE/H/1397/01-05/DC Ramipril/Amlodipine Sandoz (ramipril/amlodipine) Applicant: Sandoz A/S This module reflects the scientific discussion for the approval
More informationEfficacy of Moxidectin 6-Month Injectable and Milbemycin Oxime/Lufenuron Tablets Against Naturally Acquired Toxocara canis Infections in Dogs*
Efficacy of Moxidectin 6-Month Injectable and Milbemycin Oxime/Lufenuron Tablets Against Naturally Acquired Toxocara canis Infections in Dogs* Dwight D. Bowman, MS, PhD a Walter Legg, DVM b David G. Stansfield,
More informationPharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension Formulations in Human Volunteers
R Iranian Journal of Pharmaceutical Sciences Summer 2006: 2(3): 129-136 www.ijps.ir Original Article Pharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystimex, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients: Methyl parahydroxybenzoate 1 mg Sodium
More informationOral sedation of horses
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Oral sedation of horses Author : Aimi Duff Categories : Equine, Vets Date : September 28, 2015 Sedation is sometimes necessary
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationDon t let arthritis slow down your dog!
Don t let arthritis slow down your dog! abcd DOG CAT ACUTE CHRONIC PERIOPERATIVE INJECTABLE ORAL SUSPENSION CHEWABLE Keeping your dog in the prime of life Is your dog at risk of developing arthritis? As
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS page 1 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur PetPaste 187.5 mg/g oral paste for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g oral
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Zantel Cat and Dog Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances (per tablet): Praziquantel Fenbendazole
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HALOCUR 0.5 mg/ml oral solution for calves 2. Qualitative and quantitative composition Active substance Halofuginone
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationComparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle
Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,
More informationMeloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
Inflamm. res. 50, Supplement 1 (2001) S5 S9 1023-3830/01/01S5-05 $ 1.50+0.20/0 Birkhäuser Verlag, Basel, 2001 Inflammation Research Meloxicam: a review of its pharmacokinetics, efficacy and tolerability
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 250 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PT, RO,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One g contains:
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Clomicalm 5 mg tablets for dogs Clomicalm 20 mg tablets for dogs Clomicalm 80 mg tablets for dogs 2. QUALITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationPharmacokinetics of amoxycillin and clavulanic acid in
Br. J. clin. Pharmac. (1988), 26, 385-390 Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin B. E. DAVIES', R. BOON2, R. HORTON2,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NexGard 11 mg chewable tablets for dogs 2 4 kg NexGard 28 mg chewable tablets for dogs >4 10 kg NexGard 68 mg chewable
More informationCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
PFIZER INC. PFIZER ANIMAL HEALTH USA Product Label http://www.vetdepot.com 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269 833 4000 Customer Service: 800 733 5500 and 800 793 0596 Veterinary Medical
More informationA New Advancement in Anesthesia. Your clear choice for induction.
A New Advancement in Anesthesia Your clear choice for induction. By Kirby Pasloske When using Alfaxan, patients should be continuously monitored, and facilities for maintenance of a patent airway, artificial
More informationGastric Dilatation-Volvulus
Gastric Dilatation-Volvulus The term "ACVS Diplomate" refers to a veterinarian who has been board certified in veterinary surgery. Only veterinarians who have successfully completed the certification requirements
More informationYOU CAN ALWAYS HAVE CONFIDENCE IN QUALITY. The Intervet/Schering-Plough Animal Health range of Injectable Antibiotics.
YOU CAN ALWAYS HAVE CONFIDENCE IN QUALITY The Intervet/Schering-Plough Animal Health range of Injectable Antibiotics. Intervet/Schering-Plough Animal Health committed to success With a heritage that includes
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur AquaSol 200 mg/ml oral suspension for use in drinking water for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationLefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
More informationVeterinary Parasitology 112 (2003)
Veterinary Parasitology 112 (2003) 249 254 Comparative speed of kill between nitenpyram, fipronil, imidacloprid, selamectin and cythioate against adult Ctenocephalides felis (Bouché) on cats and dogs R.
More informationApril 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1. SUMMARY OF THE DOSSIER Rheumocam is a generic medicinal product as defined in Article 13(2) (b) of Directive 2001/82/EC, as amended by Directive 2004/28/EC. The reference veterinary
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationUSA Product Label CERENIA INJECTABLE SOLUTION. Pfizer Animal Health. (maropitant citrate) Antiemetic. For subcutaneous injection in dogs and cats
PFIZER INC. PFIZER ANIMAL HEALTH USA Product Label http://www.vetdepot.com 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Customer Service: 800-733-5500 and 800-793-0596 Veterinary Medical
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prazitel Plus XL Tablets For Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substances: Praziquantel
More informationAnesthesia Check-off Form
Anesthesia Check-off Form 5231 SW 91st Drive Gainesville, FL 32608 (352) 377-6003 The doctors and staff at Haile Plantation Animal Clinic would like to offer the most advanced medical care and services
More informationDay 90 Labelling, PL LABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE : Carton 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Alvegesic vet. 10 mg/ml Solution for injection for Horses, Dogs
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationTablet. A light-brown to brown, meat flavoured, bone shaped tablet scored on both sides that can be divided into halves.
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Drontal Dog Tasty Bone 150/144/50 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active Substances: 150 mg Febantel 50 mg Pyrantel
More informationDrug therapy of Filariasis. Dr. Shareef sm Asst. professor pharmacology
Drug therapy of Filariasis Dr. Shareef sm Asst. professor pharmacology Signs and symptoms Lymphatic filariasis Fever Inguinal or axillary lymphadenopathy Testicular and/or inguinal pain Skin exfoliation
More information